viewGenprex, Inc.

Genprex CEO updates investors on recent $10mln capital raise, progress of cancer-fighting drug Oncoprex

Genprex (NASDAQ:GNPX) CEO Rodney Varner updates Proactive's Christine Corrado on the Austin, Texas-based biopharma's operations in the last few months, notably raising $10mln to be used toward continuing the company's clinical trial of Oncoprex,. Enrollment in Phase 1 and 2 studies for the cancer fighting drug has resumed. Varner also talks about Genprex's agreement with the University of Texas MD Anderson Cancer Center.

Varner is in New York to speak to investors at the H.C. Wainwright & Co. 20th Annual Investor Conference.

Quick facts: Genprex, Inc.

Price: 2.24 USD

Market: NASDAQ
Market Cap: $73.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...



Full interview: Genprex makes key hires to its board and executive team

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the gene therapy group has made a few key hires despite the economic downturn due to the coronavirus. Varner says the biotech has bolstered its board with three new directors, in addition to appointing two life sciences executives,...

1 week, 4 days ago

2 min read